MiniMed Group, Inc. (MMED) Stock Price & How to Invest

MiniMed Group is Medtronic's former Diabetes business, headquartered in Northridge, California, with about 8,000 employees and products sold in about 80 countries. It makes automated insulin delivery systems (the MiniMed 780G, and since 2026 the smaller MiniMed Flex), MiniMed Go smart insulin pens, Simplera continuous glucose monitors, and sells the Instinct sensor made by Abbott, all tied together by its own algorithms and app. CEO Que Dallara leads the company.

The separation ran in two steps. On March 9, 2026 MiniMed completed an IPO of 28 million shares at $20 each while Medtronic kept the large majority. On October 15, 2026 Medtronic completed an exchange offer in which its shareholders swapped about 55 million Medtronic shares for about 252.8 million MiniMed shares; the offer was 5.4 times subscribed, and Medtronic no longer owns any MiniMed stock. MiniMed named a reshaped eight-member board the next day.

Financially, MiniMed booked about $2.96 billion of sales in its fiscal year ended April 2026 with a net loss of about $331 million, and trailing revenue has reached about $3.22 billion. Its fiscal first quarter of 2027 (ended July 31, 2026) brought $843 million of sales, up 16.6% reported (low double digits excluding an extra week), with US sales up 13% and international up 18%. Gross margin runs near 57% while operating margin is close to zero, so the investment case rests on growth and scale bringing profits through.

MiniMed is unprofitable on a GAAP basis (trailing net loss about $314 million, operating cash flow negative) and has a thin cash balance of about $207 million on its latest balance sheet, so execution on the margin plan matters. Competition is intense: Insulet, Tandem, Dexcom and Abbott each have strong positions, and GLP-1 drugs could change how many type 2 patients need intensive insulin therapy. MiniMed depends partly on Abbott for a sensor. The company has a history of FDA warning letters and recalls under Medtronic. New standalone costs and transition agreements with Medtronic add uncertainty. Supply overhang is a near-term risk: about 253 million shares reached former Medtronic holders on October 15, 2026, and the stock fell about 19% in the month before the exchange closed.

15 analysts publish price targets on MMED, averaging $25.00 against a $17.49 price as of October 2026, or +42.9%. The published targets run from $15.00 to $30.00, a moderate spread, and the ratings split 12 buy, 3 hold, 1 sell. Over the last six months there have been 9 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full MMED forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on MiniMed Group, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. A full US product cycle. MiniMed has lost US share to Insulet's Omnipod and Tandem over several years. The most optimistic published target, $30.00, assumes this works close to its best case.

The case against. MiniMed is unprofitable on a GAAP basis (trailing net loss about $314 million, operating cash flow negative) and has a thin cash balance of about $207 million on its latest balance sheet, so execution on the margin plan matters. The most pessimistic target, $15.00, is roughly what MMED is worth if this bites instead.

Read the full bull and bear case on MMED, including what would have to change to break either one. Walnut is not an investment adviser.

No. MiniMed Group, Inc. (MMED) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see MiniMed Group, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$3.2 billion; latest quarter up ~17% year over year
• Gross / operating margin: ~57% / ~0.5%
• Net income (TTM): ~-$314 million; EPS about -$1.53
• P/E (forward): ~25x (forward EPS ~$0.69)
• Price to sales: ~1.5x
• Market cap: ~$4.9 billion (share price ~$17.58)
• FY2027 guidance: ~10.5% organic growth, ~16% adjusted EBITDA margin
• Dividend: None

At about 1.5 times sales, MiniMed trades at a steep discount to faster-growing, profitable diabetes-device peers, a gap that reflects its GAAP losses, its recent US share losses and the overhang from Medtronic's exit. On forward earnings the multiple is about 25x. The 15 covering analysts rate it a buy with a mean target near $25, and Rothschild & Co Redburn initiated at buy with a $30 target on October 13, 2026.

Other names that sit close to MMED: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get MMED exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so MMED sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where MMED fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

MiniMed (MMED) is a newly independent, roughly $3.2 billion-revenue insulin-pump and CGM maker growing about 16-17% with a product pipeline (Flex, the Fit patch pump, the Vivera fully closed-loop algorithm) aimed at winning back US share from Insulet and Tandem. It is still loss-making on a GAAP basis, so the shares trade on revenue growth and margin expansion, and on how the stock settles after Medtronic's exit flooded the market with about 253 million new shares.

Whether MMED is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is MMED a buy or a sell?, and where the stock could go from here in the MMED stock forecast.

For income investors, whether MMED pays a dividend and how the payout looks is covered in does MMED pay a dividend? And to weigh MMED against a peer, read the full side-by-side comparisons: MMED vs PODD and MMED vs TNDM.